Literature DB >> 15373889

Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.

P H Chandrasekar1, J L Cutright, E K Manavathu.   

Abstract

The efficacy of voriconazole in combination with amphotericin B or micafungin was studied in a transiently neutropenic guinea-pig model of invasive pulmonary aspergillosis. Guinea-pigs treated with the antifungal drugs, alone or in two-drug combinations, had an improved survival rate and reduced fungal burden in the lungs compared to untreated control animals. The efficacy of monotherapy and combination therapy was similar; activity was neither enhanced nor reduced with the two-drug combinations. Further studies of efficacy, dosing and optimal regimens for antifungal combinations are warranted.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15373889     DOI： 10.1111/j.1469-0691.2004.00958.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  24 in total

1.  Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

Authors:  Carly G Dennis; William R Greco; Yseult Brun; Richard Youn; Harry K Slocum; Ralph J Bernacki; Russell Lewis; Nathan Wiederhold; Steven M Holland; Ruta Petraitiene; Thomas J Walsh; Brahm H Segal
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.

Authors:  Kathrin Heyn; Antje Tredup; Stefanie Salvenmoser; Frank-Michael C Müller
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 4.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 5.  Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Zahida Bhatti; Aasma Shaukat; Nikolaos G Almyroudis; Brahm H Segal
Journal:  Mycopathologia       Date:  2006-07       Impact factor: 2.574

6.  Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Maria Siopi; Nikolaos Siafakas; Sophia Vourli; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

7.  Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.

Authors:  Enrique Calvo; F Javier Pastor; Valentina Salas; Emilio Mayayo; Josep Guarro
Journal:  Mycopathologia       Date:  2011-12-04       Impact factor: 2.574

8.  In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

Authors:  A Raffetin; V Courbin; V Jullien; E Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

9.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

10.  Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.

Authors:  Ana C Vallor; William R Kirkpatrick; Laura K Najvar; Rosie Bocanegra; Marsha C Kinney; Annette W Fothergill; Monica L Herrera; Brian L Wickes; John R Graybill; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.